Skip to main content

Pavaki Capital Management LLC

SEC CIK
0002143027
Latest filing
Aug 7, 2026

The latest 13F from Pavaki Capital Management LLC covers Q2 2026 (filed Aug 7, 2026): 132 long positions worth $175.5M. The top 10 holdings make up 47.9% of the portfolio, and the largest is Chevron Corp (CVX) at 9.2%. Livermore has 4 filings on Form 13F from this institution, going back to Q4 2025.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
17
Est. +$29.9M
Added
14
Est. +$17.9M
Reduced
2
Est. −$19.2M
Sold out
6
Est. −$5.89M

Top 5 holdings

Share of this quarter's portfolio value

  1. CVXChevron Corp
    9.2%$16.1MHistory
  2. MISTMilestone Pharmaceuticals Inc.
    6.9%$12.2MHistory
  3. INTUIntuit Inc.
    5.7%$10.1MHistory
  4. QCOMQualcomm Inc
    5.2%$9.05MHistory
  5. BBarrick Mining Corp
    4.6%$8.14MHistory

Share of portfolio

Top 5 holdings and the other 127 positions, by share of portfolio value

  1. CVX9.2%
  2. MIST6.9%
  3. INTU5.7%
  4. QCOM5.2%
  5. B4.6%
  6. Other 127 positions68.4%

Biggest buys

New and added positions, by estimated amount bought

  1. INTUIntuit Inc.
    +$10.1MNewHistory
  2. QCOMQualcomm Inc
    +$9.05MNewHistory
  3. MUMicron Technology Inc
    +$4.62MNewHistory
  4. TXTTextron Inc
    +$3.82MAddedHistory
  5. CVXChevron Corp
    +$3.73MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. INTUIntuit Inc.
    +5.74 pp0.0% → 5.7%History
  2. QCOMQualcomm Inc
    +5.16 pp0.0% → 5.2%History
  3. MUMicron Technology Inc
    +2.63 pp0.0% → 2.6%History
  4. TXTTextron Inc
    +1.78 pp2.6% → 4.4%History
  5. SLBSLB Limited
    +1.04 pp0.6% → 1.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. INTCIntel Corp
    −$13.4MReducedHistory
  2. DISWalt Disney Co
    −$5.78MReducedHistory
  3. OGNOrganon & Co.
    −$1.97MSold outHistory
  4. SPHRSphere Entertainment Co.
    −$1.39MSold outHistory
  5. ESPREsperion Therapeutics, Inc.
    −$1.12MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. DISWalt Disney Co
    −4.08 pp4.1% → 0.1%History
  2. INTCIntel Corp
    −2.78 pp3.1% → 0.3%History
  3. OGNOrganon & Co.
    −1.38 pp1.4% → 0.0%History
  4. SPHRSphere Entertainment Co.
    −0.98 pp1.0% → 0.0%History
  5. ESPREsperion Therapeutics, Inc.
    −0.79 pp0.8% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$175.5M
+$33.2M (+23.3%) vs. prior quarter
Positions
132
+11 vs. prior quarter
Top 10 concentration
47.9%
Top 10 as share of value
Turnover
15.8%
Q2 2026, one quarter
Average holding period
2.6 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2025), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q4 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $175.5M (Q2 2026)

Q4 2025: $143.2MQ1 2026: $142.3MQ2 2026: $175.5M
Q4 2025Q2 2026
13F filings of Pavaki Capital Management LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 7, 2026132$175.5MCVXMISTINTUvs. Q1 2026SEC
Q1 2026Aug 7, 2026121$142.3MCVXMISTBvs. Q4 2025SEC
Q4 2025Aug 7, 2026Amended95$143.2MMISTREGNSPRY–SEC

13D and 13G filings

Companies where Pavaki Capital Management LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Pavaki Capital Management LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
MISTMilestone Pharmaceuticals Inc.13G7.30%9.07M sharesNewAug 7, 20261 filingAug 7, 2026SEC

Latest filings

1 filing on file made by Pavaki Capital Management LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Pavaki Capital Management LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
MISTMilestone Pharmaceuticals Inc.Aug 7, 20261:49 PM ET13G7.30%9.07M sharesNewDec 31, 2025SEC